[Form 4] Axsome Therapeutics, Inc Insider Trading Activity

Rhea-AI Filing Summary

Axsome Therapeutics, Inc. (AXSM) director Mark Coleman reported open-market purchases of the issuer's common stock on 09/08/2025. The Form 4 lists three purchase transactions totaling 1,575 shares at prices of $127.20, $127.30, and $127.40, recorded as purchases. After these transactions Mr. Coleman is reported to beneficially own 48,212 shares directly. The filing also discloses 403,856 shares held indirectly by an entity over which he has voting and dispositive power, for a combined reported beneficial interest of 452,068 shares as shown on the form. The purchases were executed in the open market and the Form 4 was signed by an attorney-in-fact on 09/09/2025. Footnotes clarify the open-market nature of the purchases and the basis for indirect beneficial ownership.

Positive

• Open-market purchases disclosed totaling 1,575 shares on 09/08/2025, showing clear and timely insider reporting
• Detailed beneficial ownership disclosed: 48,212 shares direct and 403,856 shares indirect, with footnotes explaining indirect ownership

Negative

• None.

Insights

Securities Analyst

TL;DR: Director executed small open-market purchases totaling 1,575 shares; filing shows substantial indirect holdings.

Mark Coleman made three open-market purchases on 09/08/2025 totaling 1,575 shares at roughly $127.2–$127.4 per share. The reported direct share count rose to 48,212, while an entity for which he has voting and dispositive power holds 403,856 shares indirectly. For a securities analyst, these are routine insider buy transactions recorded on Form 4 and do not, by themselves, indicate material corporate changes. The disclosure is clear on transaction type, prices, and the distinction between direct and indirect holdings.

Corporate Governance Expert

TL;DR: Governance filing correctly discloses director-level purchases and indirect holdings; no governance concerns disclosed.

The Form 4 identifies Coleman as a director and reports open-market acquisitions with explicit footnotes explaining indirect ownership via an entity under his control. The filing appears complete for Section 16 reporting: it specifies transaction dates, codes, amounts, prices, and post-transaction beneficial ownership counts and includes a signature by an attorney-in-fact. There is no indication of amendments, derivatives, or procedural irregularities in the provided content.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Coleman Mark

(Last) (First) (Middle)

C/O AXSOME THERAPEUTICS, INC.

ONE WORLD TRADE CENTER, 29TH FLOOR

(Street)

NEW YORK NY 10007

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Axsome Therapeutics, Inc. [ AXSM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/08/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/08/2025		P(1)		800	A	$127.2	47,437	D
Common Stock	09/08/2025		P(1)		287	A	$127.3	47,724	D
Common Stock	09/08/2025		P(1)		488	A	$127.4	48,212	D
Common Stock								403,856	I	See Footnote(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the open market purchase of shares of the Issuer's common stock.

2. Such shares are held by an entity, of which the reporting person has voting and dispositive power, and therefore, the reporting person is deemed to be the indirect beneficial owner of such shares.

	/s/ Nick Pizzie, Attorney-in-Fact	09/09/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transactions did Mark Coleman report on Form 4 for AXSM?

The Form 4 reports three open-market purchases on 09/08/2025 totaling 1,575 shares at prices of $127.20, $127.30, and $127.40.

How many AXSM shares does Mark Coleman beneficially own after the reported transactions?

The filing reports 48,212 shares directly and 403,856 shares indirectly, for a combined reported beneficial interest of 452,068 shares.

What is the nature of the indirect holdings reported by Mark Coleman?

Footnote (2) states the 403,856 shares are held by an entity of which Mr. Coleman has voting and dispositive power, making him an indirect beneficial owner.

Were the reported transactions purchases or sales?

All three reported transactions are open-market purchases (transaction code P) executed on 09/08/2025.

Who signed the Form 4 and when?

The form was signed by /s/ Nick Pizzie, Attorney-in-Fact on 09/09/2025.